Soluble Mesothelin Related Peptide (SMRP) and Osteopontin (OPN) as Early Detection Markers for Malignant Mesothelioma (MM)
- Chia, David — University of California, Los Angeles
- Feng, Ziding — Fred Hutchinson Cancer Research Center
- Srivastava, Sudhir — National Cancer Institute
- Rom, William — New York University School of Medicine
- Robinson, Bruce — University of Western Australia
- Black, Brad — Center for Asbestos Related Diseases
- Pass, Harvey Ira — New York University School of Medicine
- Nilsson, Olle — Fujirebio Diagnostics, Inc.
Phase I: - Identification and assemblage of representative cohorts of individuals with MM, no malignancies but increased risk for MM due to asbestos exposure, and (optionally) lung malignancies other than MM Phase II (A) - Determine the sensitivity and specificity of SMRP and OPN in distinguishing individuals with a clinical diagnosis of malignant mesothelioma from individuals who are asbestos-exposed but without a clinical diagnosis of malignant mesothelioma. Phase II (B) – Determine the comparability of analyte values across contributing centers and determine covariates that influence analyte levels Phase II (C) – Determine the sensitivity and specificity of SMRP and OPN, alone and in combination, in distinguishing individuals with MM from those without. Phase III. Determine the sensitivity and specificity of SMRP and OPN in distinguishing individuals who would subsequently develop malignant mesothelioma from matched individuals who did not subsequently develop malignant mesothelioma. Phase IV. Determine the sensitivity and specificity of SMRP and OPN in other populations of interest.
No datasets are currently associated with this protocol.